ASCVD - Atherosclerotic Cardiovascular Disease
Conditions
Brief summary
CHD death-based MACE plus
Detailed description
3-point MACE, CV death-based MACE plus, Coronary heart disease death or MI, Cardiovascular death, All-cause death, Time to first event of MI, ischemic stroke, acute limb ischemia or major amputation, and urgent arterial revascularization, Percent change from baseline in LDL-C, Percent change from baseline in Apolipoprotein B, Percent change from baseline in Non-HDL-C, Percent change from baseline in Lipoprotein (a), Number of participants with an adverse event (AE), Number of participants discontinuing from study intervention due to AE
Interventions
Sponsors
Merck Sharp & Dohme LLC
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CHD death-based MACE plus | — |
Secondary
| Measure | Time frame |
|---|---|
| 3-point MACE, CV death-based MACE plus, Coronary heart disease death or MI, Cardiovascular death, All-cause death, Time to first event of MI, ischemic stroke, acute limb ischemia or major amputation, and urgent arterial revascularization, Percent change from baseline in LDL-C, Percent change from baseline in Apolipoprotein B, Percent change from baseline in Non-HDL-C, Percent change from baseline in Lipoprotein (a), Number of participants with an adverse event (AE), Number of participants discontinuing from study intervention due to AE | — |
Countries
Denmark, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Spain
Outcome results
None listed